SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus

Autores
Alkayyal, Almohanad A.; Ajina, Reham; Cacciabue, Marco Polo Domingo; Alkayyal, Aaesha A.; Saeedi, Nizar H.; Hussain Alshehry, Taofik; Kaboha, Feras; Alotaibi, Mohammed A.; Zaidan, Nada; Shah, Khalid; Alroqi, Fayhan; Bakur Mahmoud, Ahmad
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent.
Fil: Alkayyal, Almohanad A.. King Abdullah International Medical Research Center, Riyadh; Arabia Saudita. University of Tabuk; Arabia Saudita
Fil: Ajina, Reham. Abdulaziz University; Arabia Saudita. King Abdullah International Medical Research Center, Riyadh; Arabia Saudita
Fil: Cacciabue, Marco Polo Domingo. Universidad Nacional de Luján; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro Regional Buenos Aires; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Agrobiotecnología y Biología Molecular. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Alkayyal, Aaesha A.. Taibah University; Arabia Saudita
Fil: Saeedi, Nizar H.. University of Tabuk; Arabia Saudita
Fil: Hussain Alshehry, Taofik. King Saud University; Arabia Saudita
Fil: Kaboha, Feras. King Saud University; Arabia Saudita
Fil: Alotaibi, Mohammed A.. University of Tabuk; Arabia Saudita. King Saud University; Arabia Saudita
Fil: Zaidan, Nada. King Abdulaziz City For Science And Technology; Arabia Saudita
Fil: Shah, Khalid. Harvard Medical School; Estados Unidos
Fil: Alroqi, Fayhan. National Guard Health Affairs; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia Saudita
Fil: Bakur Mahmoud, Ahmad. Taibah University; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia Saudita
Materia
B16F10 MELANOMA MODELS
ONCOLYTIC VIROTHERAPY
SARS-COV-2 RBD
VSV-Δ51 ENHANCEMENT
VSV-Δ51 PRODUCTION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/229703
Acceder
id CONICETDig_f895df73fb7100becf801bcb2c918add
oai_identifier_str oai:ri.conicet.gov.ar:11336/229703
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virusAlkayyal, Almohanad A.Ajina, RehamCacciabue, Marco Polo DomingoAlkayyal, Aaesha A.Saeedi, Nizar H.Hussain Alshehry, TaofikKaboha, FerasAlotaibi, Mohammed A.Zaidan, NadaShah, KhalidAlroqi, FayhanBakur Mahmoud, AhmadB16F10 MELANOMA MODELSONCOLYTIC VIROTHERAPYSARS-COV-2 RBDVSV-Δ51 ENHANCEMENTVSV-Δ51 PRODUCTIONhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent.Fil: Alkayyal, Almohanad A.. King Abdullah International Medical Research Center, Riyadh; Arabia Saudita. University of Tabuk; Arabia SauditaFil: Ajina, Reham. Abdulaziz University; Arabia Saudita. King Abdullah International Medical Research Center, Riyadh; Arabia SauditaFil: Cacciabue, Marco Polo Domingo. Universidad Nacional de Luján; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro Regional Buenos Aires; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Agrobiotecnología y Biología Molecular. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Alkayyal, Aaesha A.. Taibah University; Arabia SauditaFil: Saeedi, Nizar H.. University of Tabuk; Arabia SauditaFil: Hussain Alshehry, Taofik. King Saud University; Arabia SauditaFil: Kaboha, Feras. King Saud University; Arabia SauditaFil: Alotaibi, Mohammed A.. University of Tabuk; Arabia Saudita. King Saud University; Arabia SauditaFil: Zaidan, Nada. King Abdulaziz City For Science And Technology; Arabia SauditaFil: Shah, Khalid. Harvard Medical School; Estados UnidosFil: Alroqi, Fayhan. National Guard Health Affairs; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia SauditaFil: Bakur Mahmoud, Ahmad. Taibah University; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia SauditaFrontiers Media2023-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/229703Alkayyal, Almohanad A.; Ajina, Reham; Cacciabue, Marco Polo Domingo; Alkayyal, Aaesha A.; Saeedi, Nizar H.; et al.; SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus; Frontiers Media; Frontiers in Immunology; 14; 1-2023; 1-71664-3224CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2023.1082191info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1082191/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:39:03Zoai:ri.conicet.gov.ar:11336/229703instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:39:03.664CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
title SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
spellingShingle SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
Alkayyal, Almohanad A.
B16F10 MELANOMA MODELS
ONCOLYTIC VIROTHERAPY
SARS-COV-2 RBD
VSV-Δ51 ENHANCEMENT
VSV-Δ51 PRODUCTION
title_short SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
title_full SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
title_fullStr SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
title_full_unstemmed SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
title_sort SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
dc.creator.none.fl_str_mv Alkayyal, Almohanad A.
Ajina, Reham
Cacciabue, Marco Polo Domingo
Alkayyal, Aaesha A.
Saeedi, Nizar H.
Hussain Alshehry, Taofik
Kaboha, Feras
Alotaibi, Mohammed A.
Zaidan, Nada
Shah, Khalid
Alroqi, Fayhan
Bakur Mahmoud, Ahmad
author Alkayyal, Almohanad A.
author_facet Alkayyal, Almohanad A.
Ajina, Reham
Cacciabue, Marco Polo Domingo
Alkayyal, Aaesha A.
Saeedi, Nizar H.
Hussain Alshehry, Taofik
Kaboha, Feras
Alotaibi, Mohammed A.
Zaidan, Nada
Shah, Khalid
Alroqi, Fayhan
Bakur Mahmoud, Ahmad
author_role author
author2 Ajina, Reham
Cacciabue, Marco Polo Domingo
Alkayyal, Aaesha A.
Saeedi, Nizar H.
Hussain Alshehry, Taofik
Kaboha, Feras
Alotaibi, Mohammed A.
Zaidan, Nada
Shah, Khalid
Alroqi, Fayhan
Bakur Mahmoud, Ahmad
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv B16F10 MELANOMA MODELS
ONCOLYTIC VIROTHERAPY
SARS-COV-2 RBD
VSV-Δ51 ENHANCEMENT
VSV-Δ51 PRODUCTION
topic B16F10 MELANOMA MODELS
ONCOLYTIC VIROTHERAPY
SARS-COV-2 RBD
VSV-Δ51 ENHANCEMENT
VSV-Δ51 PRODUCTION
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent.
Fil: Alkayyal, Almohanad A.. King Abdullah International Medical Research Center, Riyadh; Arabia Saudita. University of Tabuk; Arabia Saudita
Fil: Ajina, Reham. Abdulaziz University; Arabia Saudita. King Abdullah International Medical Research Center, Riyadh; Arabia Saudita
Fil: Cacciabue, Marco Polo Domingo. Universidad Nacional de Luján; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro Regional Buenos Aires; Argentina. Instituto Nacional de Tecnología Agropecuaria. Centro de Investigación en Ciencias Veterinarias y Agronómicas. Instituto de Agrobiotecnología y Biología Molecular. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Alkayyal, Aaesha A.. Taibah University; Arabia Saudita
Fil: Saeedi, Nizar H.. University of Tabuk; Arabia Saudita
Fil: Hussain Alshehry, Taofik. King Saud University; Arabia Saudita
Fil: Kaboha, Feras. King Saud University; Arabia Saudita
Fil: Alotaibi, Mohammed A.. University of Tabuk; Arabia Saudita. King Saud University; Arabia Saudita
Fil: Zaidan, Nada. King Abdulaziz City For Science And Technology; Arabia Saudita
Fil: Shah, Khalid. Harvard Medical School; Estados Unidos
Fil: Alroqi, Fayhan. National Guard Health Affairs; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia Saudita
Fil: Bakur Mahmoud, Ahmad. Taibah University; Arabia Saudita. King Saud Bin Abdulaziz University For Health Sciences; Arabia Saudita
description Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor milieu. The VSV-Δ51 oncolytic virus has been widely used as an anticancer agent with a high selectivity profile. In this study, we examined the role of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in enhancing VSV-Δ51 viral production and oncolytic activity. To test this hypothesis, we first generated a novel VSV-Δ51 mutant that encoded the SARS-COV-2 RBD and compared viral spreading and viral yield between VSV-Δ51-RBD and VSV-Δ51 in vitro. Using the viral plaque assay, we demonstrated that the presence of the SARS-CoV-2 RBD in the VSV-Δ51 genome is associated with a significantly larger viral plaque surface area and significantly higher virus titers. Subsequently, using an ATP release-based assay, we demonstrated that the SARS-CoV-2 RBD could enhance VSV-Δ51 oncolytic activity in vitro. This observation was further supported using the B16F10 tumor model. These findings highlighted a novel use of the SARS-CoV-2 RBD as an anticancer agent.
publishDate 2023
dc.date.none.fl_str_mv 2023-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/229703
Alkayyal, Almohanad A.; Ajina, Reham; Cacciabue, Marco Polo Domingo; Alkayyal, Aaesha A.; Saeedi, Nizar H.; et al.; SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus; Frontiers Media; Frontiers in Immunology; 14; 1-2023; 1-7
1664-3224
CONICET Digital
CONICET
url http://hdl.handle.net/11336/229703
identifier_str_mv Alkayyal, Almohanad A.; Ajina, Reham; Cacciabue, Marco Polo Domingo; Alkayyal, Aaesha A.; Saeedi, Nizar H.; et al.; SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus; Frontiers Media; Frontiers in Immunology; 14; 1-2023; 1-7
1664-3224
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fimmu.2023.1082191
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1082191/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614414601289728
score 13.070432

Publicaciones similares